Braidwell LP Invests $26.47 Million in Oruka Therapeutics, Inc. $ORKA

Braidwell LP bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, Holdings Channel reports. The firm bought 278,164 shares of the company’s stock, valued at approximately $26,473,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sei Investments Co. grew its holdings in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after buying an additional 13,164 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $15,313,000. Dimensional Fund Advisors LP purchased a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $5,543,000. The Manufacturers Life Insurance Company boosted its position in shares of Oruka Therapeutics by 18.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after acquiring an additional 11,205 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Oruka Therapeutics during the 1st quarter valued at approximately $1,811,000. 56.44% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ORKA. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Guggenheim reissued a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, UBS Group boosted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 158,116 shares of company stock valued at $13,523,783 in the last three months. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $91.63 on Thursday. The company has a market cap of $6.07 billion, a PE ratio of -45.14 and a beta of -0.34. Oruka Therapeutics, Inc. has a 1 year low of $14.66 and a 1 year high of $115.51. The stock’s 50 day simple moving average is $95.11 and its two-hundred day simple moving average is $69.01.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts expect that Oruka Therapeutics, Inc. will post -2.33 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.